Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Akero Therapeutics verkündet positive Ergebnisse einer Phase-2b-Studie für sein Medikament Efruxifermin gegen MASH. Aktie steigt um 100 %.
Der Portfolio-Builder ist eine starke Software-Lösung, mit der regelbasierte Portfoliokonzepte erstellt und zurückgetestet werden können.
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Lets find out.
Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion), as the Danish drugmaker seeks funding for...
Der dänische Pharmakonzern Novo Nordisk ist noch nicht satt und will weiter zukaufen. Nach der erst kürzlich angestoßenen Übernahme von Akero Therapeutics legen die Dänen...
Akero Therapeutics Inc receives Investment Bank Analyst Rating Update
